Approximately $91 billion was spent on cancer drugs last year, and yet it takes 10 to 15 years and up to $1.2 billion to bring a new cancer drug to market. Are big pharma companies the best home for drug development?

Attend The Economist Events' War on Cancer conference on September 29th to explore how to close the gaps that remain in the FDA drug-approval process and find ways for further collaboration between research and development. Gain perspective from senior thought leaders and contribute to the important discussions most pertinent to the pharmaceutical industry today, including:

• Money misspent?:
  Improving cancer research for new therapies and diagnostics
• Billion-dollar roulette:
  Can investment in drug discovery become more efficient?
• The outcomes game:
  Synthesising approaches to cancer diagnostics and therapies

FEATURED SPEAKERS:

		Martha Donoghue Clinical reviewer, hematology and oncology products US Food and Drug Administration			John Lin, MD Senior vice-president, chief scientific officer Pfizer Worldwide Research & Development
		Jennifer Malin Vice-president, clinical strategy Anthem			Bahija Jallal Executive vice-president, AstraZeneca and director, MedImmune

 

Platinum sponsor	Gold sponsor